Drug Combination Details
| General Information of the Combination (ID: C14802) | |||||
|---|---|---|---|---|---|
| Name | Beta asarone NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CYB5R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | ||
| SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | |||
| MKN74 | CVCL_2791 | Gastric tubular adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The increase of chemotherapy sensitization by Beta-asarone is associated with the inhibition of tumor glycolysis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Beta-Asarone Increases Chemosensitivity by Inhibiting Tumor Glycolysis in Gastric Cancer. Evid Based Complement Alternat Med. 2020 Apr 10;2020:6981520. | |||
